Citations 2
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Brown, Patrick A. , Aoun, Patricia, Boyer, Michael W., Burke, Patrick W. , Dinner, Shira, Fathi, Amir T. , Kirby, Suzanne, Liedtke, Michaela , Litzow, Mark R. , Luger, Selina M. , Maness, Lori J., Massaro, Stephanie, Mattison, Ryan J. , May, William , Oluwole, Olalekan O. , Park, Jae H. , Uy, Geoffrey L. , Vusirikala, Madhuri , Wieduwilt, Matthew J. , Lynn, Beth, Berardi, Ryan A., Freedman-Cass, Deborah A., Campbell, Mallory, Oluwole, Olalekan O , Uy, Geoffrey , Shah, Bijal , Advani, Anjali S. , DeAngelo, Daniel J. , Gauthier, Jordan , Jain, Nitin , Logan, Aaron C , Przespolewski, Amanda , Rangaraju, Sravanti , Rubnitz, Jeffrey E.
Journal of the National Comprehensive Cancer Network | September 22, 2021 | Volume: 19 | Issue: 9 | Pages: 1079-1109
The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, Manisha H. , Benson, Al B. , Bergsland, Emily K. , Blaszkowsky, Lawrence S. , Brock, Pamela , Chan, J.K.C., Das, Satya , Dickson, Paxton V. , Fanta, Paul T. , Giordano, Thomas J. , Halperin, Daniel M. , He, Jin , Heaney, Anthony P. , Heslin, Martin J. , Kandeel, Fouad , Kardan, Arash , Khan, Sajid , Kuvshinoff, Boris W. , Miller, Kimberly D. , Reidy‐Lagunes, Diane , Salgado, Sarimar Agosto , Shaheen, Shagufta , Sussman, Craig, Trikalinos, Nikolaos A. , Uboha, N., Vijayvergia, Namrata , Lynn, Beth, Hochstetler, Cindy, Trikalinos, Nikolaos A , Goldner, Whitney Sears , Hálfdánarson, Þorvarður R. , Lieu, Christopher H. , Pillarisetty, Venu Gopal , Soares, Heloisa P. , Soulen, Michael C , Strosberg, Jonathan , Wong, Terence Z.
Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 839-868
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.